Released Apr 2, 2018, after the close
10-K filed Apr 2, 2018, 92 days after period end · 0001564590-18-007402
Q4 2017 · 10-K
Revenue$993.00K$993.00K no prior Q4 2016 on file+66.3% vs Q3 2017
Net Income-$13.86M-$13.86M N/M vs Q4 2016N/M vs Q3 2017
EPS Diluted-$1.59-$1.59 N/M vs Q4 2016N/M vs Q3 2017
Operating Incomederived-$14,000,000—
Operating Cash Flowderived-$12,740,000N/M
Margins · derived
Operating margin-1409.9%
Net margin-1396.0%
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-K.
Same quarter
| Metric | Q4 2017 | Q4 2016 |
|---|---|---|
| Revenue | $993.00K | — |
| Net Income | -$13.86M | -$7.21M |
| EPS Diluted | -$1.59 | -$25.68 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR